Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 24, 2013, Pages 10003-10015

  Hua, Zihao ^a   Bregman, Howard ^a   Buchanan, John L ^a   Chakka, Nagasree ^a   Guzman Perez, Angel ^a   Gunaydin, Hakan ^a   Huang, Xin ^a   Gu, Yan ^a   Berry, Virginia ^a   Liu, Jingzhou ^a   Teffera, Yohannes ^a   Huang, Liyue ^a   Egge, Bryan ^a   Emkey, Renee ^a   Mullady, Erin L ^a   Schneider, Steve ^a   Andrews, Paul S ^a   Acquaviva, Lisa ^a   Dovey, Jennifer ^a   Mishra, Ankita ^a   Newcomb, John ^a   Saffran, Douglas ^a   Serafino, Randy ^a   Strathdee, Craig A ^a   Turci, Susan M ^a   Stanton, Mary ^b   Wilson, Cindy ^a   Dimauro, Erin F ^a   more..

^a Department of Chemistry Research and Discovery ^*  (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ((4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)THIO)N (TRANS 4 (5 PHENYL 1,3,4 OXADIAZOL 2 YL)CYCLOHEXYL)PROPANAMIDE; 3 (4 OXO 3,4 DIHYDRO 2 QUINAZOLINYL)N (4 (5 PHENYL 1,3,4 OXADIAZOL 2 YL)CYCLOHEXYL)PROPANAMIDE; 3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)N (4 (2 PHENYL 1H IMIDAZOL 5 YL)PHENYL)PROPANAMIDE; 3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)N (4 (2 PHENYLTHIAZOL 4 YL)PHENYL)PROPANAMIDE; 3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)N (4 (3 PHENYL 1,2,4 OXADIAZOL 5 YL)PHENYL)PROPANAMIDE; 3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)N (4 (5 PHENYL 1,3,4 OXADIAZOL 2 YL)PHENYL)PROPANAMIDE; AXIN; BETA CATENIN; N (2 METHOXY 6 METHYLPHENYL) 4 (3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)PROPANAMIDO)BENZAMIDE 2,2,2 TRIFLUOROACETATE; N (2 METHOXYPHENYL) 2 METHYL 4 ((3 (4 OXO 3,4 DIHYDRO 2 QUINAZOLINYL)PROPANOYL)AMINO)BENZAMIDE; N (2 METHOXYPHENYL) 4 (3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)PROPANAMIDO)BENZAMIDE; N (2 METHOXYPHENYL) 4 (3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)PROPANAMIDO)CYCLOHEXANECARBOXAMIDE; N (2 METHOXYPHENYL)N METHYL 4 (3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)PROPANAMIDO)BENZAMIDE 2,2,2 TRIFLUOROACETATE; N (4 (1 METHYL 1H BENZO[D]IMIDAZOL 2 YL)PHENYL) 3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)PROPANAMIDE; N (4 (1 METHYL 1H INDAZOL 3 YL)PHENYL) 3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)PROPANAMIDE; N (4 (BENZO[D]OXAZOL 2 YL)PHENYL) 3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)PROPANAMIDE; N (4 (N (2 METHOXYPHENYL)SULFAMOYL)PHENYL) 3 (4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)PROPANAMIDE; TANKYRASE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOPHORE; TIME TO MAXIMUM PLASMA CONCENTRATION; WNT SIGNALING PATHWAY;

EID: 84891305943     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401317z     Document Type: Article

References (31)

1. Clevers, H. Wnt/β-catenin signaling in development and disease Cell 2006, 127, 469-480
2. Reya, T.; Clevers, H. Wnt signaling in stem cells and cancer Nature 2005, 434, 843
3. Barker, N.; Clevers, H. Mining the Wnt pathway for cancer therapeutics Nat. Rev. Drug Discovery 2006, 5, 997-1014
4. Polakis, P. The many ways of Wnt in cancer Curr. Opin. Genet. Dev. 2007, 17, 45-51
5. Martin, S. A.; Lord, C. J.; Ashworth, A. DNA repairs deficiency as a therapeutic target in cancer Curr. Opin. Genet. Dev. 2008, 18, 80-86
6. Jones, P. Development of poly(ADP-ribose)polymerase (PARP) inhibitors in oncology Annu. Rep. Med. Chem. 2010, 45, 229-243
7. Ferraris, D. V. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic J. Med. Chem. 2010, 53, 4561-4584
8. Smith, S.; Giriat, I.; Schmitt, A.; de Lange, T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres Science 1998, 282, 1484-1487
9. Riffell, J. L.; Lord, C. J.; Ashworth, A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family Nat. Rev. Drug Discovery 2012, 11, 923-936
10. Lehtiö, L.; Chi, N.-W.; Krauss, S. Tankyrase as drug targets FEBS J. 2013, 280, 3576-3593 and references herein.
11. Waaler, J.; Ondrej, M.; Lucie, T.; Huyen, D.; Vladimir, K.; Ray, W. S.; Erik, P. J.; Marie, P. N.; Tor, J. E.; Olga, M.; Gradl, D.; Voronkov, A.; von Kries, J. P.; Krauss, S. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice Cancer Res. 2012, 72 (11) 2822-2832 and references herein.
12. Huang, S. M.; Mishina, Y. M.; Liu, S.; Cheung, A.; Stegmeier, F.; Michaud, G. A.; Charlat, O.; Wiellette, E.; Zhang, Y.; Wiessner, S.; Hild, M.; Shi, X.; Wilson, C. J.; Mickanin, C.; Myer, V.; Fazal, A.; Tomlinson, R.; Serluca, F.; Shao, W.; Cheng, H.; Shultz, M.; Rau, C.; Schirle, M.; Schlegl, J.; Ghidelli, S.; Fawell, S.; Lu, C.; Curtis, D.; Kirschner, M. W.; Lengauer, C.; Finan, P. M.; Tallarico, J. A.; Bouwmeester, T.; Porter, J. A.; Bauer, A.; Cong, F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signaling Nature 2009, 46, 614-620
13. Chen, B.; Dodge, M. E.; Tang, W.; Lu, J.; Ma, Z.; Fan, C.-W.; Wei, S.; Hao, W.; Kilgore, J.; Williams, N. S.; Roth, M. G.; Amatruda, J. F.; Chen, C.; Lum, L. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer Nat. Chem. Biol. 2009, 5 (2) 100-107
14. Lu, J.; Ma, Z.; Hsieh, J.-C.; Fan, C.-W.; Chen, B.; Longgood, J. C.; Williams, N. S.; Amatruda, J. F.; Lum, L.; Chen, C. Structure-activity relationship studies of small-molecule inhibitors of Wnt response Bioorg. Med. Chem. Lett. 2009, 19 (14) 3825-3827
15. Karlberg, T.; Markova, N.; Johansson, I.; Hammarstrom, M.; Schutz, P.; Weigelt, J.; Schuler, H. Structural basis for the interaction between tankyrase-2 and potent wnt-signaling inhibitor J. Med. Chem. 2010, 53, 5352-5355
16. Gunaydin, H.; Gu, Y.; Huang, X. Novel binding mode of a potent and selective tankyrase inhibitor PLoS One 2012, 7, e333740
17. Narwal, M.; Venkannagari, H.; Lehtiö, L. Structural basis of selective inhibition of human tankyrase J. Med. Chem. 2012, 55, 1360-1367
18. Waaler, J.; Machon, O.; von Kries, J. P.; Wilson, S. R.; Lundenes, E.; Wedlich, D.; Gradl, D.; Paulsen, J. E.; Machonova, O.; Dembinski, J. L.; Dinh, H.; Krauss, S. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth Cancer Res. 2011, 71, 197-205
19. Shultz, M. D.; Kirby, C. A.; Stams, T.; Chin, D. N.; Blank, J.; Charlat, O.; Cheng, H.; Cheung, A.; Cong, F.; Feng, Y.; Fortin, P. D.; Hood, T.; Tyagi, V.; Xu, M.; Zhang, B.; Shao, W. [1,2,4]Triazol-3-ylsulfanylmethyl)-3-phenyl-[1, 2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding J. Med. Chem. 2012, 55, 1127-1136
20. Voronkov, A.; Holsworth, D. D.; Waaler, J.; Wilson, S. R.; Ekblad, B.; Perdreau-Dahl, H.; Dinh, G.; Drewes, G.; Hopf, C.; Morth, J. P.; Krauss, S. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor J. Med. Chem. 2013, 56, 3012-3023
21. Lau, T.; Chan, E.; Callow, M.; Waaler, J.; Boggs, J.; Blake, R. A.; Magnuson, S.; Sambrone, A.; Schutten, M.; Firestein, R.; Machon, O.; Korinek, V.; Choo, E.; Diaz, D.; Merchant, M.; Polakis, P.; Holsworth, D. D.; Krauss, S.; Costa, M. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth Cancer Res. 2013, 73, 3132-3144
22. Narwal, M.; Haikarainen, T.; Fallarero, A.; Vuorela, P. M.; Lehtiö, L. Screening and structural analysis of flavones inhibiting tankyrases J. Med. Chem. 2013, 56, 3507-3517
23. Shultz, M. D.; Cheung, A. K.; Kirby, C. A.; Firestone, B.; Chen, C. H.; Chen, Z.; Chin, D.; DiPietro, L.; Fazal, A.; Feng, Y.; Fortin, P. D.; Gould, T.; Lagu, B.; Lei, H.; Lenoir, F.; Majumdar, D.; Ochala, E.; Palermo, M. G.; Pham, L.; Pu, M.; Smith, T.; Stams, T.; Tomlinson, R. C.; Toure, B. B.; Visser, M.; Wang, R. M.; Waters, N. J.; Shao, W. Identification of NVP-TNKS656: the use of structure-efficiency relationships (SER) to generate a highly potent, selective and orally active tankyrase inhibitor J. Med. Chem. 2013, 56, 6495-6511
24. Shultz, M. D.; Majumdar, D.; Chin, D.; Fortin, P. D.; Feng, Y.; Gould, T.; Kirby, C. A.; Stams, T.; Waters, N. J.; Shao, W. Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases J. Med. Chem. 2013, 56, 7049-7059
25. Larsson, E. A.; Jansson, A.; Ng, F. M.; Then, S. W.; Panicker, R.; Liu, B.; Sangthongpitag, K.; Pendharkar, V.; Tai, S. J.; Hill, J.; Dan, C.; Ho, S. Y.; Cheong, W. W.; Poulsen, A.; Blanchard, S.; Lin, G. R.; Alam, J.; Keller, T. H.; Nordlund, P. Fragment-based ligand design of novel potent inhibitors of tankyrases J. Med. Chem. 2013, 56, 4497-4508
26. Bregman, H.; Chakka, N.; Guzman-Perez, A.; Gunaydin, H.; Gu, Y.; Huang, X.; Berry, V.; Liu, J.; Teffera, Y.; Huang, L.; Egge, B.; Mullady, E. L.; Schneider, S.; Andrews, P. S.; Mishra, A.; Newcomb, J.; Serafino, R.; Strathdee, C. A.; Turci, S. M.; Wilson, C.; DiMauro, E. F. The discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors J. Med. Chem. 2013, 56, 4320-4342
27. Bregman, H.; Gunaydin, H.; Gu, Y.; Schneider, S.; Wilson, C.; DiMauro, E. F.; Huang, X. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket J. Med. Chem. 2013, 56, 1341-1345
28. Floby, E.; Briem, S.; Terelius, Y.; Sohlenius-Sternbeck, A.-K. The use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations Xenobiotica 2004, 34, 949-959
29. Bissell, D. M.; Guzelian, P. S. Phenotypic stability of adult rat hepatocytes in primary monolayer culture Ann. N.Y. Acad. Sci. 1980, 249, 85-98
30. For the first example of S···Oî-C interaction, see the following: Goldstein, B. M.; Mao, D. T.; Marquez, V. E. Ara-tiazofurin: conservation of structural features in an unusual thiazole nucleoside J. Med. Chem. 1988, 31, 1026-1031
31. Huang, L.; Chen, A.; Roberts, J.; Janosky, B.; Be, X.; Berry, L.; Lin, M.-H. J. Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds Xenobiotica 2012, 42 (9) 830-840